6-氨基-(9ci)-3-吡啶甲胺 | 156973-09-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氨基-(9ci)-3-吡啶甲胺
• 中文别名: 2-氨基-5-氨甲基吡啶；6-氨基-3-吡啶甲胺；5-(氨基甲基)吡啶-2-胺
• 英文名称: 5-(aminomethyl)pyridin-2-amine
• 英文别名: 2-amino-5-aminomethyl-pyridine
• CAS: 156973-09-0
• 化学式: C₆H₉N₃
• mdl: MFCD06213156
• 分子量: 123.158
• InChiKey: PHBVTMQLXNCAQO-UHFFFAOYSA-N

物化性质

• 沸点：
  292.6±25.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 储存条件：
  存储温度应保持在2-8°C，并请避免光照。

反应信息

• 作为反应物：
  描述：

  6-氨基-(9ci)-3-吡啶甲胺 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.33h， 生成 (2S)-1-[(2R)-2-amino-3,3-dicyclohexylpropanoyl]-N-[(6-aminopyridin-3-yl)methyl]pyrrolidine-2-carboxamide
  参考文献：
  名称：

  Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position

  摘要：

  A novel class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position has been discovered. Four of these thrombin inhibitors (13b,c,e and 14d) showed nanomolar potency (K-i 0.8-12 nM), 300-1500-fold selectivity for thrombin compared with trypsin, and good oral bioavailability (F = 40-76%) in rats or dogs. The neutral Fl was expected to increase metabolic stability and oral absorption. Identification of this novel aminopyridyl group at Fl was a key step in our search for a clinical candidate.

  DOI：

  10.1021/jm970493r
• 作为产物：
  描述：

  6-氨基烟酰胺 在 盐酸 、 硼烷 作用下， 生成 6-氨基-(9ci)-3-吡啶甲胺
  参考文献：
  名称：

  Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position

  摘要：

  A novel class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position has been discovered. Four of these thrombin inhibitors (13b,c,e and 14d) showed nanomolar potency (K-i 0.8-12 nM), 300-1500-fold selectivity for thrombin compared with trypsin, and good oral bioavailability (F = 40-76%) in rats or dogs. The neutral Fl was expected to increase metabolic stability and oral absorption. Identification of this novel aminopyridyl group at Fl was a key step in our search for a clinical candidate.

  DOI：

  10.1021/jm970493r

文献信息

• 一种阿贝西利中间体化合物的制备方法
  申请人：新发药业有限公司

  公开号：CN107337634B

  公开（公告）日：2019-07-09

  本发明涉及一种阿贝西利中间体化合物的制备方法。该方法利用丁烯二腈和硝基甲烷缩合、加氢环化得到2‑氨基‑5‑氨甲基吡啶，然后和N,N‑二(2‑氯乙基)乙胺成环制备5‑(4‑乙基哌嗪‑1‑基)甲基‑2‑氨基吡啶。该化合物可用于阿贝西利的制备。本发明不使用价格昂贵的试剂、原子经济率高、副反应少，安全，产品收率和纯度高，原料价廉易得，操作简便、成本低。
• Prokineticin 1 receptor antagonists
  申请人：Coats Steven J.

  公开号：US20080269225A1

  公开（公告）日：2008-10-30

  The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

  本发明涉及某些化合物的新颖结构，其化学式为（I）：以及制备这些化合物、组合物、中间体和衍生物的方法，以及用于治疗促动素1或促动素1受体介导的疾病的方法。
• Substituted phenyl acetamides and their use as protease inhibitors
  申请人：——

  公开号：US20040254166A1

  公开（公告）日：2004-12-16

  Phenyl acetamide compounds are described, including compounds of Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 3 -R 6 , R 11 , B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  苯乙酰胺化合物的描述，包括式I的化合物： 或其溶剂化合物、水合物或药用可接受盐；其中R 3 -R 6 ，R 11 ，B，Y和W在说明书中列出。本发明的化合物是蛋白酶的强效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶和Xa因子。描述了用于抑制血小板丢失、抑制血小板聚集物形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于制造用于血液采集、血液循环和血液储存的设备中的材料中，如导管、血液透析机、血液采集器和管、血管和支架。此外，这些化合物可以被检测标记并用于体内血栓的成像。
• [EN] AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS<br/>[FR] DERIVES DE CYANURE D'AZOLE METHYLIDENE ET LEUR UTILISATION COMME MODULATEURS DE PROTEINE KINASE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003106455A1

  公开（公告）日：2003-12-24

  The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.

  本发明涉及唑衍生物，尤其是用作药物活性化合物的唑衍生物，以及包含这种唑衍生物的药物制剂。所述唑衍生物是蛋白激酶信号通路的调节剂，尤其是涉及c-Jun N端激酶和/或糖原合酶3的那一种。本发明还涉及新颖的唑衍生物以及它们的制备方法。X是O、S或NR0，其中R0是H或未取代或取代的C1-C6烷基；A是2-吡啶基，3-吡啶基，4-吡啶基，吡啶唑基，吡唑啉基，吡嗪基或三嗪基团。
• ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Arigon Jérôme

  公开号：US20120094986A1

  公开（公告）日：2012-04-19

  The invention relates to nicotinamide derivatives which can be used as anticancer drugs.

  这项发明涉及可用作抗癌药物的烟酰胺衍生物。